Abstract
Ten patients with severe rheumatoid arthritis were treated with a murine monoclonal anti-CD4 (B-F5) antibody in an open study (one with 10 mg/day, 2 with 15 mg/day, 7 with 20 mg/day) for 10 consecutive days. Tolerance was excellent. All patients improved during treatment clinically (Ritchie's index, morning stiffness, pain scale) (p = 0.005), as well as biologically C-reactive protein (p = 0.008) with an average 60% reduction of each of these variables at Day 15, and clinical benefit lasted over 6 months in some patients. No significative depletion was noted in total lymphocyte or CD3, CD4, CD8, CD20, positive cells after treatment. Evidence of murine immunization was found in only 2 patients.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Aged
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD / immunology
-
Antigens, CD20
-
Antigens, Differentiation, B-Lymphocyte / immunology
-
Antigens, Differentiation, T-Lymphocyte / immunology
-
Arthritis, Rheumatoid / immunology
-
Arthritis, Rheumatoid / therapy*
-
CD3 Complex
-
CD4 Antigens / immunology*
-
CD8 Antigens
-
Female
-
Humans
-
Immunotherapy
-
Injections, Intravenous
-
Male
-
Middle Aged
-
Receptors, Antigen, T-Cell / immunology
-
T-Lymphocytes / immunology
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, CD20
-
Antigens, Differentiation, B-Lymphocyte
-
Antigens, Differentiation, T-Lymphocyte
-
CD3 Complex
-
CD4 Antigens
-
CD8 Antigens
-
Receptors, Antigen, T-Cell